Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 19/20 | 0.57 |
| ▸ | F2 | P00734 | 5/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2233760 | 1.00 | F10 (0.57) | F10F2ABCB11ST14PTGS2 | |
| SCHEMBL16706296 | 0.86 | F10 (0.66) | F10F2ABCB11ST14PTGS2 | |
| SCHEMBL18843493 | 0.81 | F10 (0.58) | F10F2ABCB11ST14PTGS2 | |
| SCHEMBL5625141 | 0.77 | F10 (0.73) | F10F2ABCB11ST14 | |
| SCHEMBL5628214 | 0.77 | F10 (0.73) | F10F2ABCB11ST14 | |
| SCHEMBL5627627 | 0.77 | F10 (0.73) | F10F2ABCB11ST14 | |
| SCHEMBL5625381 | 0.77 | F10 (0.73) | F10F2ABCB11ST14 | |
| SCHEMBL5625917 | 0.77 | F10 (0.71) | F10F2ABCB11ST14 | |
| SCHEMBL5630405 | 0.77 | F10 (0.71) | F10F2ABCB11ST14 | |
| SCHEMBL16706293 | 0.76 | F10 (0.61) | F10F2ABCB11ST14PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648189-B2 | Method for the preparation of rivoraxaban | SANDOZ AG (CH) | 2014-02-11 | — | — | US | disclosed |
| US-20130184457-A1 | METHOD FOR THE PREPARATION OF RIVORAXABAN | SANDOZ AG (CH) | 2013-07-18 | — | — | US | disclosed |
| WO-2011098501-A1 | METHOD FOR THE PREPARATION OF RIVAROXABAN | SANDOZ AG (CH) | 2011-08-18 | — | — | WO | disclosed |
| WO-2011098501-A1 | METHOD FOR THE PREPARATION OF RIVAROXABAN | SANDOZ AG (CH) | 2011-08-18 | — | — | WO | disclosed |
| EP-2354128-A1 | Method for the preparation of rivaroxaban | SANDOZ AG (CH) | 2011-08-10 | — | — | EP | disclosed |
| EP-2354128-A1 | Method for the preparation of rivaroxaban | SANDOZ AG (CH) | 2011-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184457-A1 | METHOD FOR THE PREPARATION OF RIVORAXABAN | VKORC1, VKORC1L1, CYP3A5 | F10 49/4885F2 5/4885ABCB11 2254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.